VERICEL CORPORATION

VCEL ·Healthcare, Drug Manufacturers - General, United States
Financial Statements Income Statement
Annual Quarterly

Income Statement

Line Item FY2026 FY2025 FY2024 FY2023 FY2022 FY2021 FY2020 FY2019
Revenue $276.3M $237.2M $197.5M $164.4M $156.2M $124.2M $117.9M
Cost of Revenue $70.7M $65.1M $61.9M $54.6M $50.2M $40.0M $37.6M
Gross Profit $205.6M $172.1M $135.6M $109.8M $106.0M $84.2M $80.3M
Gross Margin 74.4% 72.6% 68.6% 66.8% 67.9% 67.8% 68.1%
Operating Expenses
Research & Development $27.6M $24.8M $21.0M $19.9M $16.3M $13.0M $30.4M
SG&A Expense $167.0M $142.8M $121.0M $106.9M $97.6M $68.8M $61.1M
Operating Income $11.0M $4.5M $-6.5M $-17.1M $-7.9M $2.4M $-11.3M
Operating Margin 4.0% 1.9% -3.3% -10.4% -5.0% 1.9% -9.5%
Interest Expense $600.0K $366.0K $4.0K $6.0K $8.0K
Pretax Income $17.4M $10.5M $-2.4M $-16.0M $-7.6M $3.0M $-9.7M
Income Tax Expense $859.0K $148.0K $814.0K $721.0K $-111.0K $180.0K $0
Net Income $16.5M $10.4M $-3.2M $-16.7M $-7.5M $2.9M $-9.7M
Net Margin 6.0% 4.4% -1.6% -10.2% -4.8% 2.3% -8.2%
EPS (Basic) $0.33 $0.21 $-0.07 $-0.35 $-0.16 $0.06 $-0.22
EPS (Diluted) $0.32 $0.20 $-0.07 $-0.35 $-0.16 $0.06 $-0.22
Shares Outstanding (Basic) 50.8M 50.3M 48.8M 47.6M 47.1M 46.5M 45.2M 44.2M
Shares Outstanding (Diluted) 50.8M 52.2M 51.7M 47.6M 47.1M 46.5M 47.3M 44.2M
Dividends Per Share
← Newer Page 1 of 3 Older →